What does Retatrutide do? Benefits and evidence

An experimental weekly injection with phase 3 weight-loss results.

Also called: LY3437943, LY-3437943, Reta.

GLP-1 / GIP / glucagon agonists · GIP, GLP-1 and glucagon receptor triple agonist.

Retatrutide is an experimental injection studied for weight loss and type 2 diabetes. It has phase 3 results and is not FDA approved. Reported effects include stomach upset, heart-rate changes and sensitive skin. Online products have unknown quality. Ask your clinician about the risks.

  • In a phase 2 trial, people on the 12 mg dose lost 24.2% of their body weight on average over 48 weeks. (Studied in a trial)
  • In adults with type 2 diabetes, trials found lower blood sugar and weight; the 12 mg group lost 18.8% on average. (Studied in a trial)
  • In phase 3 trials, people also had improvements in knee pain and sleep apnea measures. (Studied in a trial)
  • People report smoother appetite control when they raise the dose in smaller steps. (Reported by users)

Uses in the sources

  • In TRIUMPH-1, adults with obesity lost more weight than those given placebo over 80 weeks. A trial average cannot predict your result. (Studied in a trial) (source)
  • Studied for blood sugar control and weight loss in type 2 diabetes. It cannot replace insulin in type 1 diabetes. (Studied in a trial) (source)
  • Studied for sleep apnea and knee pain in obesity. Phase 3 trials reported improvements. (Studied in a trial) (source)
  • Studied for liver fat in a phase 2 substudy. Effects on liver scarring, cirrhosis and cancer remain unknown. (Studied in a trial) (source)
  • Weight loss included fat and lean tissue in adults with type 2 diabetes. These findings do not show muscle-building benefits. (Studied in a trial) (source)

Related to Retatrutide

Sources

Sources checked: 2026-10-22.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.